{"entity":{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","aka":["TRIlogy-5"],"tldr":"A phase 3 trial testing JNJ-79635322 in multiple myeloma, now recruiting.","summary":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07518186, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3 Randomised Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide. Planned enrolment is 700 participants (estimated). The study started in 2026-05-31 and primary completion is expected in 2029-04-29. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07518186","url":"https://clinicaltrials.gov/study/NCT07518186"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["jnj-79635322"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07518186","phase":"3","setting":"A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide","sponsor":"Janssen Research & Development","participation":[{"nct":"NCT07518186","source":"https://clinicaltrials.gov/study/NCT07518186","fetchedAt":"2026-10-07T16:55:47.566Z","studySha256":"76a9eeb294218fe00c716b84d6a9b006888b90dfef9bf7fa9ed6a15986ee989f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":700,"enrolmentType":"ESTIMATED","siteCount":173,"recruitingSiteCount":173,"countries":["Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","India","Israel","Italy","Japan","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United States"]}],"started":"2026-05-31","startedType":"actual","enrolled":700,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07518186/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}